Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Dr Diana Walford described the delay in construction of new facilities for PBL production as "unconscionable".

  • Read more about Dr Diana Walford described the delay in construction of new facilities for PBL production as "unconscionable".

The Policy Steering Group proposed a new laboratory be built at BPL at a cost of £21.1 million spread over the years 1982/83 to 1985/86.

  • Read more about The Policy Steering Group proposed a new laboratory be built at BPL at a cost of £21.1 million spread over the years 1982/83 to 1985/86.

Peter Wormald noted "There appear to have been some follow-up discussions, but I was not copied into the papers and I do not know what action, if any, resulted. It is possible that the discussions took a back seat in September when the Medicines Inspectors' report on BPL was presented."

  • Read more about Peter Wormald noted "There appear to have been some follow-up discussions, but I was not copied into the papers and I do not know what action, if any, resulted. It is possible that the discussions took a back seat in September when the Medicines Inspectors' report on BPL was presented."

Peter Wormald noted that "although no decision had been yet on the redevelopment of BPL, there was a need to determine its future capacity; which in turn raised the issue of what part Liberton would play in meeting capacity."

  • Read more about Peter Wormald noted that "although no decision had been yet on the redevelopment of BPL, there was a need to determine its future capacity; which in turn raised the issue of what part Liberton would play in meeting capacity."

Peter Wormald, Under-Secretary in the DHSS, understood that the reasons for the policy of self-sufficiency was "that imported products were very expensive and in general were considered to carry much higher risk of cross-infections, particularly hepatitis".

  • Read more about Peter Wormald, Under-Secretary in the DHSS, understood that the reasons for the policy of self-sufficiency was "that imported products were very expensive and in general were considered to carry much higher risk of cross-infections, particularly hepatitis".

A plasma supply target of 435,000 kilograms was broadly maintained, and although estimates thereafter continued to increase, there was a growing consensus that demand for Factor 8 would increase to the region of 100 million international units. The increases in estimated needs were by this time gradual compared to those that came before.

  • Read more about A plasma supply target of 435,000 kilograms was broadly maintained, and although estimates thereafter continued to increase, there was a growing consensus that demand for Factor 8 would increase to the region of 100 million international units. The increases in estimated needs were by this time gradual compared to those that came before.

If the PFC processed plasma to produce Factor 8 for England, then less would be needed to be spent on BPL, since BPL would then process smaller quantities of plasma, and since smaller quantities required less manufacturing space and equipment, it would cost less to build.

  • Read more about If the PFC processed plasma to produce Factor 8 for England, then less would be needed to be spent on BPL, since BPL would then process smaller quantities of plasma, and since smaller quantities required less manufacturing space and equipment, it would cost less to build.

The approval given by the Treasury in November 1982 for the reconstructed BPL was for a plant capable of fractionating 400,000 kilograms per annum.

  • Read more about The approval given by the Treasury in November 1982 for the reconstructed BPL was for a plant capable of fractionating 400,000 kilograms per annum.

Dr Lane considered in 1979 that a redeveloped BPL could be commissioned to increase production capacity to 90 million international units between 1985 and 1990, as an intermediate stage, and then to scale up production to 120 million units for the years that followed.

  • Read more about Dr Lane considered in 1979 that a redeveloped BPL could be commissioned to increase production capacity to 90 million international units between 1985 and 1990, as an intermediate stage, and then to scale up production to 120 million units for the years that followed.

The Standing Medical Advisory Committee was constituted by the National Health Service Act 1946 and Dr Waiter noted that the Committee expected an increasing requirement for Factor 8 for orthopaedic surgery and David Smart recorded the modified figures.

  • Read more about The Standing Medical Advisory Committee was constituted by the National Health Service Act 1946 and Dr Waiter noted that the Committee expected an increasing requirement for Factor 8 for orthopaedic surgery and David Smart recorded the modified figures.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 274
  • Page 275
  • Page 276
  • Page 277
  • Current page 278
  • Page 279
  • Page 280
  • Page 281
  • Page 282
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.